A Study of Acalabrutinib in Combination with Rituximab + (Bendamustine or Venetoclax) in Subjects with MCL

Trial Identifier: ACE-LY-106
Sponsor: AcertaPharma
Collaborator:
AstraZeneca
NCTID:: NCT02717624
Start Date: April 2016
Primary Completion Date: June 2022
Study Completion Date: August 2027

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version

Trial Locations

Country Location
US, OH Columbus, OH, US, 43210
US, OH Columbus, OH, US, 43210
US, OH Columbus, OH, US, 43210
US, OH Columbus, OH, US, 43210
US, OH Columbus, OH, US, 43210
US, OH Columbus, OH, US, 43210
US, OH Columbus, OH, US, 43210
US, OH Columbus, OH, US, 43210
US, OH Columbus, OH, US, 43210
US, OH Columbus, OH, US, 43210
US, OH Columbus, OH, US, 43210
US, OH Columbus, OH, US, 43210
US, OH Columbus, OH, US, 43210
US, OH Columbus, OH, US, 43210
US, OH Columbus, OH, US, 43210